FPH02 - A Phase III, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment with an Open-Label Bosentan Arm in Patients with Pulmonary Arterial Hypertension (STRIDE II).

Grants and Contracts Details

StatusFinished
Effective start/end date2/2/0412/31/06

Funding

  • ENCYSIVE LP admin by ResearchPoint: $12,450.00